No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Risk Evaluation and Mitigation Strategy (REMS) market within the context of Pharmaceutical Manufacturing is a system of processes and procedures designed to ensure the safe use of medications. It is a risk management tool used to assess, monitor, and manage the risks associated with the use of pharmaceutical products. REMS includes elements to assure safe use, such as medication guides, patient package inserts, communication plans, and elements to protect against inappropriate use, such as restricted distribution systems, patient registries, and prescriber education. REMS is an important part of the drug development process, as it helps to ensure that the benefits of a drug outweigh its risks.
Some companies in the REMS market include: Novartis, Pfizer, Merck, GlaxoSmithKline, Sanofi, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb, and Eli Lilly. Show Less Read more
